Obinutuzumab奥滨尤妥珠单抗奥滨尤妥珠单抗,949

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Obinutuzumab

CAS No. : 949142-50-1

MCE 国际站：Obinutuzumab

产品活性：Obinutuzumab (GA101) 是新型糖工程化 II 型 CD20 人源化 IgG1 单克隆抗体，用于非霍奇金淋巴瘤的研究。

研究领域：Immunology/Inflammation

作用靶点：CD20

In Vitro: Obinutuzumab is found to be superior to rituximab and ofatumumab in the induction of direct cell death (independent of mechanical manipulation required for cell aggregate disruption formed by antibody treatment), whereas it is 10 to 1,000 times less potent in mediating CDC. Obinutuzumab shows superior activity to rituximab and ofatumumab in ADCC and whole-blood B-cell depletion assays, and is comparable with these two in ADCP. Obinutuzumab also shows slower internalization rate upon binding to CD20 than rituximab and ofatumumab

In Vivo: Obinutuzumab is more active than rituximab administered at similar doses on established RL tumors. The antitumor effect of obinutuzumab against RL xenografts is dose dependent in terms of tumor growth inhibition (TGI). TGI is calculated using NCI formula at day 34 and shows values of 25, 75, and 85% for the 10, 30, and 100 mg/kg dosages of obinutuzumab, respectively. The higher doses of 30 and 100 mg/kg of obinutuzumab significantly inhibit the growth of RL tumors and result in some complete tumor remissions (10% and 30%, respectively). Tolerability of obinutuzumab with these regimens is excellent and no significant modification of body weight is observed. Obinutuzumab induces a strong antitumor effect, including complete tumor remission in the SU-DHL4 model and overall superior efficacy compared with both rituximab and ofatumumab. Obinutuzumab plus bendamustine achieves superior tumor growth inhibition versus rituximab plus bendamustine and shows a statistically significant effect versus the respective single treatments. Obinutuzumab plus chemotherapy is superior to the respective monotherapies.

相关产品：Rituximab  |  Mosunetuzumab  |  Glofitamab  |  Ofatumumab  |  Odronextamab  |  Epcoritamab  |  Blontuvetmab  |  Ocrelizumab  |  Ublituximab  |  Divozilimab  |  Eramkafusp Alfa  |  Ocaratuzumab  |  Plamotamab  |  Ripertamab  |  Tositumomab  |  Zuberitamab

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds